Donate

Rare diseases

Contrary to what may be believed, rare and genetic diseases concern all of us. They affect 4% to 6% of the population, i.e. 3 million French people and 25 to 30 million Europeans. 80% of these diseases are of genetic origin. For many years, the French Muscular Dystrophy Association (AFM-Téléthon) has been involved in research into rare diseases, and particularly in the development of innovative drugs. The Association also fights to ensure that rare diseases remain a public health priority.

Illustration for category: Information and care services

Information and care services

Contrary to what may be believed, rare and genetic diseases concern all of us. They affect 4 to 6% of the population, i.e. 3 million French people and 25 to 30 million Europeans. As the main financier of the Plateforme Maladies Rares, AFM-Téléthon works to maintain recognition of rare diseases as a public health priority, inform patients and the medical establishment and encourage the development of new treatments.
Illustration for category: Research into rare diseases funded by AFM-Téléthon

Research into rare diseases funded by AFM-Téléthon

Of the trials supported by AFM-Téléthon, nearly half of them involve non-neuromuscular rare diseases. Each of these trials is strategic because it will stimulate progress in developing treatments for other diseases. With the first successes already achieved.
Illustration for category: The National rare diseases plan

The National rare diseases plan

Along with the Alliance Maladies Rares (Rare disease alliance - a French group of patient associations), AFM-Téléthon has played a leading role in passing and drafting the first National rare diseases plan launched in 2004, now considered to be a European model.